Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 9269057)

1.
2.

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA.

Vaccine. 2013 Jan 7;31(3):524-32. doi: 10.1016/j.vaccine.2012.11.009. Epub 2012 Nov 12.

PMID:
23153449
3.

Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly.

Sastre P, Cusi MG, Manoha C, Schildgen O, Ruiz T, Vela C, Rueda P.

J Virol Methods. 2010 Sep;168(1-2):170-6. doi: 10.1016/j.jviromet.2010.05.011. Epub 2010 May 19.

PMID:
20488207
4.

Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM.

J Immunol. 2009 Nov 15;183(10):6338-45. doi: 10.4049/jimmunol.0901373. Epub 2009 Oct 19.

5.

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.

Vaccine. 2009 Sep 25;27(42):5913-9. doi: 10.1016/j.vaccine.2009.07.038. Epub 2009 Aug 3.

PMID:
19651171
6.

Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses.

Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, Venkatesan N, Leng CH, Chong P, Chow YH.

Vaccine. 2009 Sep 4;27(40):5460-71. doi: 10.1016/j.vaccine.2009.07.004. Epub 2009 Jul 19.

PMID:
19622401
7.

Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.

Nallet S, Amacker M, Westerfeld N, Baldi L, König I, Hacker DL, Zaborosch C, Zurbriggen R, Wurm FM.

Vaccine. 2009 Oct 30;27(46):6415-9. doi: 10.1016/j.vaccine.2009.06.019. Epub 2009 Jun 24.

PMID:
19559121
8.

Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.

Huang Y, Cyr SL, Burt DS, Anderson R.

J Clin Virol. 2009 Apr;44(4):287-91. doi: 10.1016/j.jcv.2009.01.009. Epub 2009 Feb 23.

PMID:
19233722
9.

Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.

Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, Wang Y, Xie C, Tang Q, Wei W, Wang M, Song J, Qu J, Zhang Y, Wang X, Hong T.

Biochem Biophys Res Commun. 2009 Apr 17;381(4):528-32. doi: 10.1016/j.bbrc.2009.02.075. Epub 2009 Feb 20.

PMID:
19233131
10.
11.

Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze.

Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, Simões EA.

J Allergy Clin Immunol. 2009 Feb;123(2):398-403. doi: 10.1016/j.jaci.2008.10.043. Epub 2008 Dec 19.

PMID:
19101023
12.

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simões EA, Wright PF, Sales VM.

J Infect Dis. 2008 Nov 1;198(9):1317-26. doi: 10.1086/592168.

13.

Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.

Hurwitz JL.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S126-8. doi: 10.1097/INF.0b013e318168b780.

PMID:
18820573
14.

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron RA.

J Infect Dis. 2008 Oct 1;198(7):1007-15. doi: 10.1086/591460.

15.

Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.

Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.

Virology. 2008 Aug 15;378(1):79-85. doi: 10.1016/j.virol.2008.04.016. Epub 2008 Jun 16.

16.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.

17.

Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.

Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE.

Vaccine. 2007 Oct 10;25(41):7132-44. Epub 2007 Aug 21.

PMID:
17850933
18.

Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.

Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, Yin X.

Vaccine. 2007 Oct 16;25(42):7422-8. Epub 2007 Aug 23.

PMID:
17850930
19.

Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.

Ternette N, Tippler B, Uberla K, Grunwald T.

Vaccine. 2007 Oct 10;25(41):7271-9. Epub 2007 Aug 23.

PMID:
17825960
20.

Human and bovine respiratory syncytial virus vaccine research and development.

Meyer G, Deplanche M, Schelcher F.

Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):191-225. Epub 2007 Aug 27. Review.

PMID:
17720245
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk